We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+50.7%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.36B
AUM Growth
+$330M
Cap. Flow
-$51.5M
Cap. Flow %
-3.79%
Top 10 Hldgs %
77.83%
Holding
43
New
3
Increased
11
Reduced
10
Closed
9

Top Buys

Rank Stock Value
1
NRIX icon
Nurix Therapeutics
NRIX
+$63.4M
2
SRRK icon
Scholar Rock
SRRK
+$49.4M
3
ANNX icon
Annexon
ANNX
+$14.3M
4
IMNM icon
Immunome
IMNM
+$12.2M
5
RAPT
RAPT Therapeutics
RAPT
+$10.4M

Top Sells

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$70.1M
2
LIVN icon
LivaNova
LIVN
+$46.2M
3
AKRO
Akero Therapeutics
AKRO
+$35.5M
4
COGT icon
Cogent Biosciences
COGT
+$21.7M
5
ETNB
89bio
ETNB
+$21.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$7.04B
$230M 16.94%
5,220,846
+1,316,390
+34% +$49.4M
KRYS icon
2
Krystal Biotech
KRYS
$10.4B
$167M 12.3%
677,705
+16,317
+2% +$3.43M
NRIX icon
3
Nurix Therapeutics
NRIX
$2.72B
$154M 11.31%
8,093,908
+4,415,514
+120% +$63.4M
STOK icon
4
Stoke Therapeutics
STOK
$2.04B
$128M 9.43%
4,034,070
-141,472
-3% -$4.25M
IMNM icon
5
Immunome
IMNM
$3.13B
$123M 9.05%
5,718,385
+695,000
+14% +$12.2M
RGNX icon
6
Regenxbio
RGNX
$638M
$62.9M 4.63%
4,368,804
-324,585
-7% -$4.05M
ADCT icon
7
ADC Therapeutics
ADCT
$146M
$55.3M 4.07%
15,666,731
– –
COGT icon
8
Cogent Biosciences
COGT
$6.02B
$51.1M 3.76%
1,437,918
-771,200
-35% -$21.7M
ANNX icon
9
Annexon
ANNX
$942M
$50.5M 3.72%
10,050,644
+3,750,000
+60% +$14.3M
BEAM icon
10
Beam Therapeutics
BEAM
$3.03B
$35.6M 2.62%
1,285,859
-101,700
-7% -$2.59M
NGNE icon
11
Neurogene
NGNE
$732M
$30.1M 2.21%
1,459,599
+160,577
+12% +$4M
RAPT
12
DELISTED
RAPT Therapeutics
RAPT
$30M 2.21%
885,927
+333,333
+60% +$10.4M
ABSI icon
13
Absci
ABSI
$1.49B
$28.8M 2.12%
8,253,316
– –
NUVB icon
14
Nuvation Bio
NUVB
$2.34B
$28.3M 2.09%
3,163,256
+132,247
+4% +$819K
IDYA icon
15
IDEAYA Biosciences
IDYA
$3.87B
$25.7M 1.89%
742,017
– –
STTK icon
16
Shattuck Labs
STTK
$707M
$20.2M 1.49%
5,539,724
– –
SLN
17
Silence Therapeutics
SLN
$834M
$13.2M 0.97%
2,164,777
– –
ZYME icon
18
Zymeworks
ZYME
$2.02B
$12.9M 0.95%
491,654
-3,214,096
-87% -$70.1M
FATE icon
19
Fate Therapeutics
FATE
$291M
$12.6M 0.93%
12,872,946
– –
REPL icon
20
Replimune Group
REPL
$1.46B
$10.7M 0.79%
1,099,756
+563,938
+105% +$4.79M
DBVT
21
DBV Technologies
DBVT
$851M
$10.5M 0.78%
+549,840
New +$8.59M
SLDB icon
22
Solid Biosciences
SLDB
$1.05B
$10.5M 0.77%
1,860,542
-38,800
-2% -$210K
CBLL
23
CeriBell Inc
CBLL
$911M
$9.54M 0.7%
435,239
– –
ESTA icon
24
Establishment Labs
ESTA
$2.11B
$8.21M 0.6%
112,664
-16,700
-13% -$1.01M
ATRA icon
25
Atara Biotherapeutics
ATRA
$92.3M
$7.99M 0.59%
441,701
– –
1
2

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2025 Portfolio in Review

As of Q4 2025, Redmile Group held 43 positions worth $1.36B, up 32% from $1.03B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Redmile Group withdrew a net $51.5M in Q4 2025, closing 9 positions and reducing 10 holdings. Its most notable exit was Akero Therapeutics, an estimated $35.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group opened a new position in DBV Technologies worth $10.5M.

  • Redmile Group's largest Q4 2025 buy was DBV Technologies: 549,840 shares worth $10.5M.
  • Redmile Group added most to Nurix Therapeutics in Q4 2025, an estimated $63.4M increase.
  • Redmile Group's biggest Q4 2025 reduction was Zymeworks, cutting an estimated $70.1M.
  • Redmile Group fully exited Akero Therapeutics in Q4 2025, selling an estimated $35.5M.
  • Redmile Group's ten largest holdings make up 78% of its $1.36B portfolio in Q4 2025.
  • Redmile Group opened 3 new positions and closed 9 in Q4 2025.
  • Redmile Group's portfolio value rose 32% quarter-over-quarter to $1.36B.

Based on Redmile Group's 13F filing for Q4 2025, filed 17 Feb 2026.